Egeler M D, van de Poll-Franse L V, Tissier R, Rogiers A, Boers-Sonderen M J, van den Eertwegh A J, Hospers G A, de Groot J W B, Aarts M J B, Kapiteijn E, Piersma D, Vreugdenhil G, van der Veldt A A, Suijkerbuijk K P M, Neyns B, Janssen K J, Blank C U, Retèl V P, Boekhout A H
Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Department of Research & Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
Qual Life Res. 2023 Sep;32(9):2517-2525. doi: 10.1007/s11136-023-03427-9. Epub 2023 Apr 20.
Checkpoint inhibitors have been shown to substantially improve the survival of patients with advanced melanoma. With this growing group of survivors treated with immunotherapies, assessing their health-state utilities is essential and can be used for the calculation of quality-adjusted life years and for cost-effectiveness analyses. Therefore, we evaluated the health-state utilities in long-term advanced melanoma survivors.
Health-state utilities were evaluated in a cohort of advanced melanoma survivors 24-36 months (N = 37) and 36-plus months (N = 47) post-ipilimumab monotherapy. In addition, the health-state utilities of the 24-36 months survivor group were assessed longitudinally, and utilities of the combined survival groups (N = 84) were compared with a matched control population (N = 168). The EQ-5D was used to generate health-state utility values, and quality-of-life questionnaires were used to establish correlations and influencing factors of utility scores.
Health-state utility scores were similar between the 24-36 months'- and the 36-plus months' survival group (0.81 vs 0.86; p = .22). In survivors, lower utility scores were associated with symptoms of depression (β = - .82, p = .022) and fatigue burden (β = - .29, p = .007). Utility scores did not significantly change after 24-36 months of survival, and the utilities of survivors were comparable to the matched control population (0.84 vs 0.87; p = .07).
Our results show that long-term advanced melanoma survivors treated with ipilimumab monotherapy experience relatively stable and high health-state utility scores.
检查点抑制剂已被证明可显著提高晚期黑色素瘤患者的生存率。随着接受免疫疗法治疗的幸存者群体不断扩大，评估他们的健康状态效用至关重要，可用于计算质量调整生命年和进行成本效益分析。因此，我们评估了长期晚期黑色素瘤幸存者的健康状态效用。
在接受伊匹单抗单药治疗后24 - 36个月（N = 37）和36个月以上（N = 47）的晚期黑色素瘤幸存者队列中评估健康状态效用。此外，对24 - 36个月幸存者组的健康状态效用进行纵向评估，并将联合生存组（N = 84）的效用与匹配的对照人群（N = 168）进行比较。使用EQ - 5D生成健康状态效用值，并使用生活质量问卷建立效用得分的相关性和影响因素。
24 - 36个月生存组和36个月以上生存组的健康状态效用得分相似（0.81对0.86；p = 0.22）。在幸存者中，较低的效用得分与抑郁症状（β = -0.82，p = 0.022）和疲劳负担（β = -0.29，p = 0.007）相关。生存24 - 36个月后，效用得分没有显著变化，幸存者的效用与匹配的对照人群相当（0.84对0.87；p = 0.07）。
我们的结果表明，接受伊匹单抗单药治疗的长期晚期黑色素瘤幸存者经历了相对稳定且较高的健康状态效用得分。
